Early High-Dose Vitamin D₃ for Critically Ill, Vitamin D-Deficient Patients.

ABSTRACT:

Background

Vitamin D deficiency is a common, potentially reversible contributor to morbidity and mortality among critically ill patients. The potential benefits of vitamin D supplementation in acute critical illness require further study.

Methods

We conducted a randomized, double-blind, placebo-controlled, phase 3 trial of early vitamin D₃ supplementation in critically ill, vitamin D-deficient patients who were at high risk for death. Randomization occurred within 12 hours after the decision to admit the patient to an intensive care unit. Eligible patients received a single enteral dose of 540,000 IU of vitamin D₃ or matched placebo. The primary end point was 90-day all-cause, all-location mortality.

Results

A total of 1360 patients were found to

SUBMITTER: National Heart, Lung, and Blood Institute PETAL Clinical Trials Network 

PROVIDER: S-EPMC7306117 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature